Promising Developments in Inovio Pharmaceuticals’ DMAb Platform Justify Buy Rating

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Inovio Pharmaceuticals (INO – Research Report), with a price target of $18.00.

Roy Buchanan’s rating is based on several promising aspects of Inovio Pharmaceuticals’ recent developments. The company’s DMAb platform has shown impressive results in its Phase 1 trial, particularly in the production of antibodies that protect against COVID-19. The durability of these antibodies, lasting up to 72 weeks, highlights the potential of Inovio’s technology to extend beyond just antibodies to other therapeutic proteins. This long-lasting expression is a significant factor in Buchanan’s positive outlook.
Furthermore, the trial demonstrated favorable pharmacokinetics and safety profiles, with no concerning adverse events or anti-drug antibodies detected. The cost and logistical advantages of DNA-based therapies over traditional monoclonal antibodies add to the platform’s appeal. Buchanan believes that with further development, Inovio’s technology could become a viable alternative in various therapeutic settings, justifying the Buy rating and the $18 price target.